MydCombi

Drug Overview

In the high-throughput environment of modern Ophthalmology, efficiency and patient comfort are critical for successful diagnostic workflows. MydCombi is a specialized pharmaceutical agent belonging to the Mydriatic / Cycloplegic Combo drug class. It is the first and only FDA-approved fixed-dose combination of tropicamide and phenylephrine delivered via a sophisticated, touchless spray system.

As a Targeted Therapy for the iris, MydCombi is designed to provide rapid and predictable pupil dilation. By combining two agents with different mechanisms of action into a single microdose, it simplifies the clinical process of preparing a patient for a comprehensive retinal exam or surgical procedure.

• Generic Name: Tropicamide and Phenylephrine Hydrochloride
• US Brand Name: MydCombi
• Drug Category: Anticholinergic and Alpha-1 Adrenergic Agonist
• Route of Administration: Topical Ophthalmic Spray (via the Optejet® dispenser)
• FDA Approval Status: FDA-approved (May 2023) for inducing mydriasis for diagnostic procedures and in conditions where short-acting pupil dilation is required.

What Is It and How Does It Work? (Mechanism of Action)

To understand how MydCombi functions, one must examine the two opposing muscles of the iris: the sphincter (which closes the pupil) and the dilator (which opens it). MydCombi utilizes a dual-action approach to “open the curtains” of the eye.

1. Tropicamide (Anticholinergic): This component blocks the muscarinic receptors in the iris sphincter muscle. By “paralyzing” the muscle that normally closes the pupil, it allows for passive dilation. It also provides a degree of Cycloplegia (paralysis of the focusing muscle), which is essential for accurate refractive measurements.
2. Phenylephrine (Alpha-1 Agonist): This component acts directly on the alpha-adrenergic receptors of the iris dilator muscle. It causes the muscle to contract, actively pulling the pupil open.
3. Synergistic Effect: By simultaneously “relaxing the closer” and “activating the opener,” MydCombi achieves a wider and faster dilation than either drug could achieve alone.
4. Micro-dose Delivery: Unlike traditional drops that “flood” the eye with excess fluid, the Optejet system delivers a fine mist of approximately 8 microliters. This is roughly 20% of the volume of a standard drop, which reduces systemic absorption and minimizes the overflow that often causes patient discomfort.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for MydCombi is the induction of Mydriasis (Pupil Dilation) for diagnostic eye examinations. It is used to provide a clear view of the lens, vitreous, and retina during dilated fundus exams.

Other Approved & Off-Label Uses

While its primary role is diagnostic, the pharmacology of this combination is utilized in various Ophthalmology scenarios:

• Comprehensive Retinal Exams: Allowing the specialist to screen for diabetic retinopathy, macular degeneration, and retinal tears.
• Pre-Operative Preparation: Dilating the eye in the minutes leading up to cataract surgery or vitrectomy.
• Short-acting Cycloplegia: Used in pediatric and adult refractions to determine the true “base” prescription of the eye.
• Post-Operative Management: Occasionally used off-label to prevent the iris from sticking to a new intraocular lens (synechiae prevention).

Dosage and Administration Protocols

MydCombi is administered in the clinic setting using the proprietary Optejet electronic dispenser.

Specific Instructions for Administration:

• Electronic Delivery: The dispenser is held approximately 1 inch from the eye. It uses a blue light to help the patient align their gaze.
• No Punctal Occlusion Needed: Because the dose is so small (micro-dose), there is typically no excess fluid to drain into the tear ducts, making traditional punctal occlusion less critical than with standard drops.
• Wait Time: Maximum dilation is typically reached within 20 to 30 minutes after administration.
• Duration: The effects typically last for 3 to 8 hours, depending on the patient’s iris pigmentation (darker eyes may dilate more slowly and stay dilated longer).

Clinical Efficacy and Research Results

Clinical data from the MIRA trials (2021–2023) confirmed that MydCombi provides a robust and consistent dilation that is non-inferior to traditional drops.

• Dilation Success: In clinical trials, over 94% of eyes achieved a pupil diameter of 6 mm or greater (the threshold for a high-quality exam) within 30 minutes.
• Micro-dose Accuracy: Research shows that the Optejet system successfully delivers the medication to the ocular surface in over 98% of attempts, even in patients who tend to blink during drop instillation.
• OCT Stabilization: By providing a wide, stable pupil, MydCombi is efficacious in ensuring the highest quality imaging for Optical Coherence Tomography (OCT) and fundus photography.
• Patient Preference: In comparative studies, over 80% of patients preferred the micro-mist spray over traditional eye drops due to the lack of “stinging” and excess fluid running down the face.

Disclaimer: The medical information provided in this guide is intended for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, ophthalmologist, or other qualified healthcare provider regarding any medical condition, eye health concerns, or treatment plan.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for MydCombi.

Common Side Effects

• Blurred Vision: Expected due to the paralysis of the focusing muscles (cycloplegia).
• Photophobia: Extreme sensitivity to light while the pupils are dilated.
• Mild Stinging: Reported in a small percentage of patients, though significantly less frequent than with standard drops.

Serious Adverse Events (Rare)

• Angle-Closure Glaucoma: A risk in patients with “narrow angles.” Dilating these patients can cause a sudden, dangerous spike in Intraocular Pressure (IOP).
• Blood Pressure Elevation: Phenylephrine is a vasoconstrictor; although systemic absorption is minimal with MydCombi, it should be used with caution in patients with uncontrolled hypertension or heart disease.
• Central Nervous System Effects: Rare in adults, but can occur in pediatric patients (restlessness, hallucinations).

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Angle Screening: A slit-lamp exam or Van Herick test is mandatory to ensure the patient does not have narrow angles before dilation.
• Baseline Diagnostics: Visual Acuity and IOP check.
• Medical History: Checking for severe hypertension, history of stroke, or sensitivity to anticholinergic drugs.

Monitoring and Precautions

• Vigilance: Patients are monitored in the waiting room for signs of an allergic reaction or an “angle-closure” event (sudden pain and nausea).
• Lifestyle Instructions:
  • UV Protection: Patients must wear dark sunglasses after the exam to protect the retina from UV damage while the pupil is unable to constrict.
  • Driving: Patients should be advised not to drive or operate machinery until the blurry vision and light sensitivity have fully resolved.
• Do’s and Don’ts:
  • DO provide the patient with disposable “post-mydriatic” sunglasses.
  • DON’T instill if the patient has had a recent spike in eye pressure.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. MydCombi is a prescription medication administered by a licensed healthcare professional. Information is accurate as of April 2026. Always consult an Ophthalmologist or Optometrist for clinical decisions.